Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRMDNYSE:NVRONASDAQ:RXSTNASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRMDIradimed$58.10-0.1%$52.40$41.69▼$63.29$738.74M0.9143,082 shs59,181 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81771,452 shs753,602 shsRXSTRxSight$15.05-7.3%$16.20$12.53▼$60.81$659.54M1.32697,181 shs1.33 million shsSIBNSI-BONE$18.86-0.6%$15.62$11.70▼$20.05$803.72M0.82377,894 shs437,967 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRMDIradimed0.00%+13.72%+9.75%+7.77%+37.71%NVRONevro0.00%0.00%0.00%+2.11%-36.80%RXSTRxSight0.00%-4.02%+0.47%-46.93%-75.07%SIBNSI-BONE0.00%+2.61%+37.87%+4.08%+39.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRMDIradimed4.7203 of 5 stars2.53.02.54.43.53.31.9NVRONevro0.2031 of 5 stars1.00.00.00.00.61.70.6RXSTRxSight3.0502 of 5 stars4.21.00.00.03.52.50.6SIBNSI-BONE3.8696 of 5 stars2.53.00.03.34.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRMDIradimed 3.00Buy$72.0023.92% UpsideNVRONevro 1.92Reduce$5.36-8.29% DownsideRXSTRxSight 2.30Hold$37.90151.83% UpsideSIBNSI-BONE 3.00Buy$22.5019.30% UpsideCurrent Analyst Ratings BreakdownLatest NVRO, SIBN, IRMD, and RXST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.005/6/2025SIBNSI-BONETruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.005/6/2025SIBNSI-BONECantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/6/2025SIBNSI-BONENeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.004/9/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$45.00 ➝ $16.004/4/2025RXSTRxSightJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Underweight$40.00 ➝ $17.004/3/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $22.004/3/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$36.00 ➝ $22.004/3/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$43.00 ➝ $43.003/21/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $36.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRMDIradimed$75.15M9.83$1.45 per share40.12$5.66 per share10.27NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72RXSTRxSight$148.31M4.12N/AN/A$4.47 per share3.37SIBNSI-BONE$176.60M4.55N/AN/A$4.18 per share4.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRMDIradimed$19.23M$1.5538.7329.05N/A26.26%24.12%21.20%8/7/2025 (Estimated)NVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)RXSTRxSight-$48.61M-$0.67N/AN/AN/A-23.92%-14.00%-12.51%8/4/2025 (Estimated)SIBNSI-BONE-$43.34M-$0.64N/AN/AN/A-23.82%-22.51%-16.53%8/4/2025 (Estimated)Latest NVRO, SIBN, IRMD, and RXST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 million5/5/2025Q1 2025SIBNSI-BONE-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million3/4/2025Q4 2024NVRONevro-$0.79-$0.64+$0.15-$1.41$102.61 million$105.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRMDIradimed$0.681.17%N/A43.87%1 YearsNVRONevroN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ASIBNSI-BONEN/AN/AN/AN/AN/ALatest NVRO, SIBN, IRMD, and RXST DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025IRMDIradimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRMDIradimedN/A9.217.82NVRONevro0.675.023.76RXSTRxSightN/A12.6711.71SIBNSI-BONE0.228.257.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRMDIradimed92.34%NVRONevro95.52%RXSTRxSight78.78%SIBNSI-BONE98.11%Insider OwnershipCompanyInsider OwnershipIRMDIradimed36.80%NVRONevro3.20%RXSTRxSight9.36%SIBNSI-BONE4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRMDIradimed11012.72 million7.97 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableRXSTRxSight22040.64 million36.53 millionOptionableSIBNSI-BONE35042.62 million40.30 millionOptionableNVRO, SIBN, IRMD, and RXST HeadlinesRecent News About These CompaniesSI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Two Sigma Advisers LPJune 1 at 4:00 AM | marketbeat.com15,454 Shares in SI-BONE, Inc. (NASDAQ:SIBN) Bought by Man Group plcMay 29 at 3:48 AM | marketbeat.comSI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025May 28, 2025 | globenewswire.comSI-BONE’s SWOT analysis: stock poised for growth amid market expansionMay 28, 2025 | investing.comWall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?May 26, 2025 | zacks.comNuveen Asset Management LLC Has $17.72 Million Stake in SI-BONE, Inc. (NASDAQ:SIBN)May 26, 2025 | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Lazard Asset Management LLCMay 23, 2025 | marketbeat.comNorthern Trust Corp Increases Holdings in SI-BONE, Inc. (NASDAQ:SIBN)May 23, 2025 | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) Shares Acquired by Paradigm Capital Management Inc. NYMay 22, 2025 | marketbeat.comVirtus Investment Advisers Inc. Acquires Shares of 13,950 SI-BONE, Inc. (NASDAQ:SIBN)May 21, 2025 | marketbeat.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 2,424 Shares of StockMay 21, 2025 | insidertrades.comSilvercrest Asset Management Group LLC Boosts Position in SI-BONE, Inc. (NASDAQ:SIBN)May 19, 2025 | marketbeat.comMercer Global Advisors Inc. ADV Invests $210,000 in SI-BONE, Inc. (NASDAQ:SIBN)May 19, 2025 | marketbeat.comGraham Capital Management L.P. Invests $498,000 in SI-BONE, Inc. (NASDAQ:SIBN)May 18, 2025 | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 4,937 SharesMay 17, 2025 | marketbeat.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 4,937 Shares of StockMay 16, 2025 | insidertrades.comParkman Healthcare Partners LLC Acquires 31,284 Shares of SI-BONE, Inc. (NASDAQ:SIBN)May 16, 2025 | marketbeat.comDimensional Fund Advisors LP Has $4.97 Million Holdings in SI-BONE, Inc. (NASDAQ:SIBN)May 15, 2025 | marketbeat.comSI-BONE (NASDAQ:SIBN) Sets New 12-Month High - What's Next?May 14, 2025 | marketbeat.com4 Recent Earnings Winners Riding Fresh Momentum in May (SIBN)May 14, 2025 | marketbeat.comWhat Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?May 13, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVRO, SIBN, IRMD, and RXST Company DescriptionsIradimed NASDAQ:IRMD$58.10 -0.04 (-0.07%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$57.98 -0.12 (-0.21%) As of 05/30/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.RxSight NASDAQ:RXST$15.05 -1.18 (-7.27%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$15.14 +0.09 (+0.60%) As of 05/30/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.SI-BONE NASDAQ:SIBN$18.86 -0.12 (-0.63%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$18.89 +0.03 (+0.13%) As of 05/30/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
